[go: up one dir, main page]

WO2023288056A3 - Compositions and methods for expansion of hla-e-restricted t cell populations - Google Patents

Compositions and methods for expansion of hla-e-restricted t cell populations Download PDF

Info

Publication number
WO2023288056A3
WO2023288056A3 PCT/US2022/037279 US2022037279W WO2023288056A3 WO 2023288056 A3 WO2023288056 A3 WO 2023288056A3 US 2022037279 W US2022037279 W US 2022037279W WO 2023288056 A3 WO2023288056 A3 WO 2023288056A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
restricted
compositions
expansion
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/037279
Other languages
French (fr)
Other versions
WO2023288056A2 (en
WO2023288056A8 (en
Inventor
Adam PARKS
Daniel Bednarik
Mathias Oelke
Han MYINT
Charles Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neximmune Inc
Original Assignee
Neximmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neximmune Inc filed Critical Neximmune Inc
Publication of WO2023288056A2 publication Critical patent/WO2023288056A2/en
Publication of WO2023288056A3 publication Critical patent/WO2023288056A3/en
Publication of WO2023288056A8 publication Critical patent/WO2023288056A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

In various aspects and embodiments, the invention provides recombinant HLA- E ligands engineered for presentation of peptide antigens to HLA-E-restricted T cells, and HLA-E ligands engineered to reduce or eliminate interaction with NKG2A/CD94. The HLA-E ligands described herein are useful for aAPC platforms for modulating T cell functions in vivo or ex vivo.
PCT/US2022/037279 2021-07-15 2022-07-15 Compositions and methods for expansion of hla-e-restricted t cell populations Ceased WO2023288056A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222211P 2021-07-15 2021-07-15
US63/222,211 2021-07-15

Publications (3)

Publication Number Publication Date
WO2023288056A2 WO2023288056A2 (en) 2023-01-19
WO2023288056A3 true WO2023288056A3 (en) 2023-02-16
WO2023288056A8 WO2023288056A8 (en) 2023-05-11

Family

ID=84919667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/037279 Ceased WO2023288056A2 (en) 2021-07-15 2022-07-15 Compositions and methods for expansion of hla-e-restricted t cell populations

Country Status (1)

Country Link
WO (1) WO2023288056A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081226A1 (en) * 2004-12-17 2009-03-26 Inserm (Institut National De La Sante Et De La Recherche Medicle) Soluble HLA-E Molecules And Their Use For Diagnosing And Treating Pathologies
WO2020047502A1 (en) * 2018-08-31 2020-03-05 3T Biosciences, Inc. Randomized peptide libraries presented by human leukocyte antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081226A1 (en) * 2004-12-17 2009-03-26 Inserm (Institut National De La Sante Et De La Recherche Medicle) Soluble HLA-E Molecules And Their Use For Diagnosing And Treating Pathologies
WO2020047502A1 (en) * 2018-08-31 2020-03-05 3T Biosciences, Inc. Randomized peptide libraries presented by human leukocyte antigens

Also Published As

Publication number Publication date
WO2023288056A2 (en) 2023-01-19
WO2023288056A8 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
MX2023001962A (en) Anti-cd28 and/or anti-b7h3 compositions.
CO2019013001A2 (en) Cytokine grafted antibody proteins and methods of use in cancer treatment
CL2022003406A1 (en) Peptides and their combinations for use in immunotherapy against ovarian cancer among others (divisional application of 201902093)
BRPI0309868B8 (en) methods of preparing a reduced lower conjugate fraction composition
WO2018081789A8 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
WO2022036142A3 (en) Ras neoantigens and uses thereof
WO2024073723A3 (en) Anti-cd122 antibodies and uses thereof
WO2022115641A3 (en) Antigen specific t cells and methods of making and using same
SA522432641B1 (en) T composition for regulatory cell culture and use
WO2021183675A3 (en) Methods for generating engineered memory-like nk cells and compositions thereof
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
CL2022003382A1 (en) a*03-restricted peptides, use in cancer immunotherapy and related methods (split application 202003371)
WO2023288056A3 (en) Compositions and methods for expansion of hla-e-restricted t cell populations
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MX2023001262A (en) Serum half-life extended pd-l1 inhibitory polypeptides.
MX2022008485A (en) A method of engineering natural killer cells to target cd70-positive tumors.
MX2024015610A (en) Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2022229884A3 (en) Recombinant antigen presenting cells
WO2019226974A3 (en) Cell-penetrating peptides and methods of use thereof
WO2006012404A3 (en) Novel cell populations and uses thereof
ZA202303966B (en) Anti-cd94 antibodies and methods of use thereof
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
WO2023137364A3 (en) Sars-cov-2 therapies
MX2023007302A (en) Antibodies against integrin alpha 11 beta 1.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22842925

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22842925

Country of ref document: EP

Kind code of ref document: A2